Coverage
Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.
Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.
Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.
Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.
Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.
A European Medicines Agency panel recommended expanding the use of a prostate cancer drug from Orion and its partner Bayer, moving the blockbuster treatment a step closer to a third approval in the region.
Filings
| Filing | Date |
|---|---|
| SHARE ACQUISITIONS 16/08/2010 | 16 Aug 2010 |
| SHARE ACQUISITIONS 13/08/2010 | 13 Aug 2010 |
| 435,019 Orion A-shares converted into B-shares | 13 Aug 2010 |
| SHARE ACQUISITIONS 12/08/2010 | 12 Aug 2010 |
| SHARE ACQUISITIONS 11/08/2010 | 11 Aug 2010 |
| CORRECTION: SHARE ACQUISITIONS 11/08/2010 | 11 Aug 2010 |
| Orion Group Interim Report January-June 2010 | 10 Aug 2010 |
| Orion Corporation's publication schedules for financial reporting in 2011 | 10 Aug 2010 |
| Orion invites analysts and media to Q2 news conference on Tuesday 10 August 2010 | 19 Jul 2010 |
| Orion and Sun settle patent dispute | 22 Jun 2010 |
| 20,138 Orion A-shares converted into B-shares | 17 Jun 2010 |
| Composition of R&D Committee as of 15 June 2010 | 15 Jun 2010 |